Patents by Inventor James Dromey
James Dromey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11123403Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: August 21, 2019Date of Patent: September 21, 2021Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20210115096Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: ApplicationFiled: May 27, 2020Publication date: April 22, 2021Applicant: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Publication number: 20200078440Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: August 21, 2019Publication date: March 12, 2020Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 10413589Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type I diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: December 12, 2018Date of Patent: September 17, 2019Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20190192624Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: December 12, 2018Publication date: June 27, 2019Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 10328124Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: May 9, 2018Date of Patent: June 25, 2019Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20190048047Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: ApplicationFiled: June 18, 2018Publication date: February 14, 2019Applicant: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Publication number: 20180256679Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: May 9, 2018Publication date: September 13, 2018Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 10010582Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: December 19, 2016Date of Patent: July 3, 2018Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20170232061Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: December 19, 2016Publication date: August 17, 2017Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Publication number: 20170158743Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: ApplicationFiled: September 9, 2016Publication date: June 8, 2017Applicant: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Patent number: 9585969Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: November 15, 2012Date of Patent: March 7, 2017Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 9464120Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: GrantFiled: August 13, 2014Date of Patent: October 11, 2016Assignee: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Publication number: 20150050303Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: ApplicationFiled: August 13, 2014Publication date: February 19, 2015Applicant: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Publication number: 20140308209Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: November 15, 2012Publication date: October 16, 2014Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 8835603Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: GrantFiled: November 30, 2009Date of Patent: September 16, 2014Assignee: ImmusanT, Inc.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din
-
Publication number: 20110293644Abstract: The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients.Type: ApplicationFiled: November 30, 2009Publication date: December 1, 2011Applicant: IMMUSANT, INC.Inventors: Robert P. Anderson, Jessica A. Stewart, James A. Dromey, Jason A. Tye-Din